Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
reMYND NV announced today that Bernd Bohrmann (Neuroscience, Roche) is presenting preclinical efficacy data at the leading AD/PD conference held March 6th-10th in Florence, on a novel combination therapy tested in an Alzheimer mouse model in collaboration with reMYND’s Contract Research Organization (CRO).
As a globally recognized research partner in Alzheimer’s, reMYND’s CRO is helping its clients in the US, Japan and throughout Europe to assess pharmacology and efficacy of experimental Alzheimer treatments, with a strong focus on in-vivo preclinical testing. reMYND’s proprietary APP-London mouse model recapitulates important pathological and clinical hallmarks of Alzheimer’s disease. This model has proven a valuable paradigm for evaluating Abeta directed approaches in general and is the preferred model for testing beta-secretase inhibitor/modulator approaches in particular. The treatment under investigation combined Roche’s BACE inhibitor R7921 and anti-Abeta-antibody gantenerumab, both currently in clinical development by Roche. The combination therapy efficiently reduced brain pathology, in particular amyloid plaque burden, even below levels at study start, which suggests clearance of pre-existing pathology and effective prevention of new pathology formation, suggesting that combining BACE inhibitor R7129 with Gantenerumab may offer enhanced clinical efficacy to treat Alzheimer's disease.
An Tanghe, Manager Contract Research at reMYND’s CRO said: “It has been a pleasure working with the Roche team and taking part in this pivotal work. The collaboration with Roche is a model for how we prefer to work with our clients, namely contributing our unique models and specialized expertise as a true research partner, so as to significantly advance the Alzheimer programs of our clients.”
Helmut Jacobsen, Project leader at Roche’s Pharma Preclinical Neuroscience Research and Study Monitor at the time of the combo study said: “We have experienced working with reMYND as very positive and we are again really pleased with the quality of the work performed in the context of this study. The fact that the presentation has been selected for an oral presentation at one of the top AD conferences testifies the relevance of the insights gained. The exciting outcome of the study will be elaborated both in a presentation at the AD/PD meeting and a joint scientific paper currently in preparation.”
For the full press release please click here.
For more information on the current offering please click here.